Results 41 to 50 of about 4,306 (252)

Clinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema:a review of the current literature [PDF]

, 2017
The first-line therapy for patients with center-involving diabetic macular edema (DME) is with intravitreal anti-vascular endothelial growth factor (VEGF) agents, with or without adjunctive macular laser treatment.
Anand, Astha, Saedon, Habiba, Yit, Yang C.   +2 more
core   +2 more sources

Efficacy and safety of fluocinolone acetonide 0.025% otic solution in patients with otic eczema: a randomized, double-blind, placebo-controlled clinical trial

Journal of International Medical Research, 2018
Objectives To assess the efficacy and safety of fluocinolone acetonide 0.025% otic solution versus placebo in treating patients with otic eczema. Methods In this multicentre, randomized, double-blind, parallel-group phase 3 clinical trial, conducted at ...
Victoria Montoro, Carlos Asensio, Ángel Martínez, Juan Lorente, Francisco J. Rodríguez, José Montojo, Javier Gavilanes, Pedro Sarría, Cristóbal Langdon, Eduard Prades   +9 more
doaj   +1 more source

Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye – evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN®)

Journal of Ophthalmic Inflammation and Infection, 2020
Background The current article is a short review of an Alimera Sciences-sponsored symposium held during The 15th International Ocular Inflammation Society Congress in Taiwan on the 14th November 2019 entitled, ‘Preventing relapse of non-infectious ...
Bahram Bodaghi, Quan Dong Nguyen, Glenn Jaffe, Ramin Khoramnia, Carlos Pavesio   +4 more
doaj   +1 more source

Use of flucinolone acetonide for patients with diabetic macular oedema:patient selection criteria and early outcomes in real world setting [PDF]

, 2016
Introduction: Fluocinolone acetonide slow release implant (Iluvien®) was approved in December 2013 in UK for treatment of eyes which are pseudophakic with DMO that is unresponsive to other available therapies.
Ajay Bhatnagar, Andrej Kidess, CS Brand, D Boyer, DM Brown, DS Boyer, DS Levin, E Chew, Fahad Quhill, Ibrahim Elaraoud, JA Wells, JW Yau, Marie Tsaloumas, MJ Elman, NZ Gregori, PA Campochiaro, PA1 Campochiaro, Walter Andreatta, Yit Yang   +18 more
core   +1 more source

A Novel Approach to Assess the Potency of Topical Corticosteroids

Pharmaceutics, 2021
The potencies of topical corticosteroid products have mainly been classified using clinical data but in some instances, the US Food and Drug Administration’s (FDA’s) vasoconstrictor assay (VCA) to assess the skin blanching response has also been used ...
Michael Zvidzayi, Seeprarani Rath, Charles Bon, Sagaran Abboo, Isadore Kanfer   +4 more
doaj   +1 more source

Corticosteroidi per via Intravitreale per il Trattamento Dell'edema Maculare: Revisione e Valutazione Della Qualità Dell'evidenza: [PDF]

, 2017
Intravitreal corticosteroids for the treatment of macular edema: review and assessment of quality of the evidenceIntroductionTreatment options for macular edema include intravitreal corticosteroids.
Luz Irene Urbina, Marco Marchetti, Marco Oradei, Matteo Ruggeri, Pierluigi Navarra   +4 more
core   +2 more sources

A PAMPA Assay as Fast Predictive Model of Passive Human Skin Permeability of New Synthesized Corticosteroid C-21 Esters

Molecules, 2012
The permeation properties of twenty newly synthesized α-alkoxyalkanoyl and α-aryloxyalkanoyl C-21 esters of standard corticosteroids: Fluocinolone acetonide, dexamethasone, triamcinolone acetonide and hydrocortisone were established using a PAMPA assay ...
Katarina D. Karljikovic-Rajic, Sote M. Vladimirov, Jadranka V. Odovic, Olivera A. Cudina, Bojan D. Markovic   +4 more
doaj   +1 more source

Fluocinolone Acetonide 0.19 mg Implant in Patients with Cystoid Macular Edema Due To Irvine–Gass Syndrome

International Medical Case Reports Journal, 2021
João Heitor Marques,1 Ana Carolina Abreu,1 Nisa Silva,1 Angelina Meireles,1,2 Bernardete Pessoa,1,2 João Melo Beirão1,2 1Serviço de Oftalmologia, Centro Hospitalar e Universitário do Porto, Porto, Portugal; 2Instituto ...
Marques JH, Abreu AC, Silva N, Meireles A, Pessoa B, Melo Beirão J   +5 more
doaj  

Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema

Journal of Ophthalmic Inflammation and Infection, 2019
Background A retrospective observational clinical study to evaluate the safety and effectiveness of the injectable 0.19-mg fluocinolone acetonide intravitreal implant (ILUVIEN) in the treatment of non-infectious uveitic macular edema.
Lea F. Weber, Stefanie Marx, Gerd U. Auffarth, Alexander F. Scheuerle, Tamer Tandogan, Christian Mayer, Ramin Khoramnia   +6 more
doaj   +1 more source

Long-term management of non-ischemic central retinal vein occlusion with fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN®)

Therapeutic Advances in Ophthalmology, 2019
Introduction: Macular edema after central retinal vein occlusion is a common cause of vision loss. Upregulation of vascular endothelial growth factor and higher levels of inflammatory mediators have been involved in the pathogeny of the macular edema in ...
João Coelho, Bernardete Pessoa, Angelina Meireles   +2 more
doaj   +1 more source